As proof of principle, we showed that the PPAR-α agonist WY14.634 induced upregulation of PPAR-α downstream genes UCP3 and MCAD [42] was reversed by GW6471 treatment in WT mice after I/R. The gene discussed is PPARA; the disease is medium chain acyl-CoA dehydrogenase deficiency.